Pinnacle Associates LTD Genmab A/S Transaction History

Pinnacle Associates LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 12, 2021	SELL	$30.92 - $44.4 $975,247 - $1.4 Million	-31,541 Closed	0 $0
Q4 2020 Jan 26, 2021	SELL	$33.66 - $40.76 $1,682 - $2,038	-50 Reduced 0.16%	31,541 $1.28 Million
Q2 2020 Aug 14, 2020	BUY	$20.05 - $33.89 $5,714 - $9,658	285 Added 0.91%	31,591 $1.07 Million
Q1 2020 May 13, 2020	SELL	$17.15 - $25.22 $7,888 - $11,601	-460 Reduced 1.45%	31,306 $663,000
Q3 2019 Nov 08, 2019	BUY	$18.0 - $21.38 $571,788 - $679,157	31,766 New	31,766 $644,000

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Pinnacle Associates LTD, based on Form 13F filings with the SEC.

Stay updated on Pinnacle Associates LTD with notifications on news.